Primary Job Title Managing Director Primary Organization 
Prospect Venture Partners
Location Palo Alto, California, United States Regions San Francisco Bay Area, Silicon Valley, West Coast Gender Male
Investor Type
David Schnell is a Managing Director of Prospect Venture Partners. David Schnell co-founded Prospect Venture Partners I with Alex Barkas, and Prospect Venture Partners II, and III with Barkas and Russell Hirsch. Prospect Ventures funds are dedicated life science funds with more than $1 billion under management. David Schnell has been actively
involved in the formation and growth of numerous successful biomedical and health care companies.
He has lead investments and served on the Board of Directors of Gloucester Pharmaceuticals (NASDAQ: CELG acquired), Healtheon (NASDAQ: HLTH), Kythera Biopharmaceuticals, Lux Biosciences, Microcide Pharmaceuticals (NASDAQ: MCDE), Neurocrine Biosciences (NASDAQ: NBIX), NGM Biopharmaceuticals, Nora Therapeutics, Rinat Neuroscience (NYSE: PFE acquired), Senomyx (NASDAQ:SNMX), Trubion Pharmaceuticals (NASDAQ: TRBN), as well as several other privately held companies.
David Schnell received an M.D. from Harvard Medical School, an M.A. in Health Services Research from Stanford University School of Medicine, and a B.S. in Biological Sciences from Stanford University.
